Cathie Wood Celebrates Black Friday by Purchasing Bitcoin ETF and Selling GitLab Shares
Cathie Wood's Trading Activity: On November 28, Cathie Wood made significant trades in ARK Invest ETFs, including fresh investments in crypto through the ARK 21Shares Bitcoin ETF, despite a shortened trading week due to Thanksgiving.
GitLab Share Sales: ARK Invest continued to reduce its position in GitLab, selling 208,528 shares worth approximately $8.46 million, following a previous sale of 646,911 shares valued at about $26.8 million.
Focus on Digital Assets: While trimming positions in software stocks, ARK increased its investment in digital assets, purchasing 70,125 shares of the ARK 21Shares Bitcoin ETF for around $425,000.
Market Trends: The ongoing interest in Bitcoin and digital assets suggests that ARK is positioning itself to capitalize on the growing attention from firms in the crypto space.
Get Free Real-Time Notifications for Any Stock
Analyst Views on EXAS
About EXAS
About the author

Abbott Laboratories Q4 2025 Results and Future Outlook
- Earnings Miss: Abbott's Q4 2025 revenue of $11.5 billion fell short of Wall Street's $11.8 billion expectation, resulting in a nearly 10% drop in stock price, reflecting investor disappointment over the nutrition segment's performance.
- Profitability Improvement: Despite the revenue miss, Abbott's adjusted diluted EPS rose 12% year-over-year, meeting analyst expectations, indicating resilience in profitability, with a projected recovery in the nutrition business expected in the second half of 2026.
- Optimistic Growth Outlook: Abbott anticipates accelerated overall revenue growth in 2026, providing guidance of 6.5% to 7.5% organic sales growth and adjusted diluted EPS of $5.55 to $5.80, showcasing the company's confidence in future performance.
- Acquisition Potential: Abbott plans to close its acquisition of Exact Sciences in Q2 2026, which is expected to introduce a new growth vertical for the company, particularly in early cancer detection, potentially becoming a key driver of strategic transformation.

Abbott Reports Disappointing Q4 Revenue, Stock Plummets
- Revenue Decline: Abbott's Q4 revenue of $11.5 billion fell short of Wall Street's $11.8 billion expectation, resulting in a nearly 10% stock drop, indicating investor disappointment with the company's performance.
- Nutrition Segment Challenges: CEO Robert Ford highlighted in the earnings call that higher manufacturing costs in the nutrition segment suppressed demand, reflecting increasing price sensitivity among consumers that impacted overall results.
- Future Growth Outlook: Abbott anticipates accelerated revenue growth in 2026, providing guidance of 6.5% to 7.5% organic sales growth, with adjusted EPS projected between $5.55 and $5.80, indicating a 10% year-over-year increase.
- Strategic Acquisition Plans: Abbott expects to close its acquisition of Exact Sciences in Q2 2026, with Ford believing this deal will introduce a new growth vertical for the company, potentially transforming its position in the early cancer detection market.









